REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
14/03/2026
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Snapshot rápido
HUMABODY
ST13
US500000079179556Classe
Pedido
Registro
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Tipo de processo
Eventos registrados
Atualização mais recente
Classificação
Tipo de marca
Classes Nice
Data de depósito
Data de registro
Data de expiração
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
Última transação
Escritório responsável
Código da situação
Cadastro oficial
Código do desenho
Tipo de titular
Localização do titular
Examinador
Localização atual
Titulares
Representantes
Rebecca Liebowitz VENABLE LLP
Classes Nice
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
chemicals used in industry and science; [ chemical test kits for in vitro testing for laboratory research purposes; ] biochemicals, namely, monoclonal antibodies and antibody fragments all being proteins for in vitro scientific and laboratory research use; biochemicals, namely, monoclonal antibodies and antibody fragments for in vitro scientific and laboratory research use; antibodies and antibody fragments all being protein in raw material form for scientific research purposes; antibody reagents used for the detection of antigens in cell and tissue analysis for scientific and laboratory in vitro diagnostic use; antibodies and antibody fragments all being proteins for industrial use in the discovery, preclinical and clinical development of therapeutic products
Classe 5
pharmaceutical preparations for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] ; veterinary preparations for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] ; therapeutic pharmaceutical preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes; antibodies being pharmaceutical preparations for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] ; antibody fragments being pharmaceutical preparations for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases] ; antibody therapeutics in the nature of therapeutic agents for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] ; medical diagnostic reagents and veterinary diagnostic reagents in the nature of antibodies and antibody fragments; antibodies and antibody fragments being therapeutic pharmaceuticals for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] and or use in the manufacture of therapeutic products
Classe 40
[ Treatment and transformation of materials for others, namely, the manufacture of chemicals, biologicals, antibodies and antibody fragments; contract manufacturing services in the field of chemicals, biologicals, antibodies and antibody fragments; custom manufacture of therapies using antibodies and antibody fragments ]
Classe 42
[ Scientific and technological services, namely, scientific research, analysis and testing and research and design in the field of chemicals, biologicals, antibodies and antibody fragments; Scientific laboratory services in the field of antibodies and antibody fragments; research in the field of the development of antibodies and antibody fragments; provision of scientific information in the field of antibodies and antibody fragments for medical and veterinary purposes; engineering of antibodies and antibody fragments; scientific services, namely, drug discovery, preclinical and clinical development of therapeutic products; consultancy services relating thereto, namely, consulting in the field of antibody and antibody fragment design ]
Histórico de despachos e eventos da marca no USPTO.
55 publicações encontradas
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
14/03/2026
PARTIAL INVALIDATION PROCESSED BY THE IB
20/06/2025
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
12/05/2025
INVALIDATION PROCESSED
12/05/2025
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
12/05/2025
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
27/02/2025
INTERNATIONAL REGISTRATION RENEWED
12/12/2024
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
08/11/2024
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
27/06/2024
REGISTERED - PARTIAL SEC 71 ACCEPTED
27/06/2024
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
07/05/2024
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
27/10/2023
TEAS SECTION 71 RECEIVED
13/09/2023
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
19/08/2023
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
14/03/2022
NEW REPRESENTATIVE AT IB RECEIVED
07/12/2017
FINAL DECISION TRANSACTION PROCESSED BY IB
14/07/2017
FINAL DISPOSITION NOTICE SENT TO IB
22/06/2017
FINAL DISPOSITION PROCESSED
22/06/2017
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
14/06/2017
REGISTERED-PRINCIPAL REGISTER
14/03/2017
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
03/02/2017
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
18/11/2016
EXTENSION OF TIME TO OPPOSE RECEIVED
18/10/2016
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
20/09/2016
PUBLISHED FOR OPPOSITION
20/09/2016
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
31/08/2016
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
31/08/2016
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
31/08/2016
LAW OFFICE PUBLICATION REVIEW COMPLETED
17/08/2016
APPROVED FOR PUB - PRINCIPAL REGISTER
09/08/2016
EXAMINER'S AMENDMENT ENTERED
09/08/2016
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
09/08/2016
EXAMINERS AMENDMENT E-MAILED
09/08/2016
EXAMINERS AMENDMENT -WRITTEN
09/08/2016
TEAS/EMAIL CORRESPONDENCE ENTERED
08/08/2016
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/08/2016
TEAS REQUEST FOR RECONSIDERATION RECEIVED
08/08/2016
NOTIFICATION OF FINAL REFUSAL EMAILED
29/07/2016
FINAL REFUSAL E-MAILED
29/07/2016
FINAL REFUSAL WRITTEN
29/07/2016
TEAS/EMAIL CORRESPONDENCE ENTERED
15/07/2016
CORRESPONDENCE RECEIVED IN LAW OFFICE
15/07/2016
ASSIGNED TO LIE
15/07/2016
TEAS CHANGE OF CORRESPONDENCE RECEIVED
11/07/2016
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/07/2016
REFUSAL PROCESSED BY IB
01/02/2016
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
11/01/2016
REFUSAL PROCESSED BY MPU
11/01/2016
APPLICATION FILING RECEIPT MAILED
08/01/2016
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/01/2016
NON-FINAL ACTION WRITTEN
05/01/2016
ASSIGNED TO EXAMINER
04/01/2016
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/01/2016
SN ASSIGNED FOR SECT 66A APPL FROM IB
03/01/2016
Proteção contínua da sua marca
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.